Literature DB >> 26032754

Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Michael Schirmer1, Christian Dejaco2, Bhaskar Dasgupta3, Eric L Matteson4.   

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.

Entities:  

Keywords:  Classification criteria; Diagnosis; Outcome; Polymyalgia rheumatica; Quality measures; Treatment

Mesh：

Substances：

Year:  2015        PMID： 26032754     DOI： 10.1007/s00296-015-3297-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  35 in total

1.  The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain.

Authors:  M A Gonzalez-Gay; C Garcia-Porrua; C Salvarani; I Olivieri; G G Hunder
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

2.  The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis.

Authors:  Eugenio De Miguel; Ana Roxo; Concepción Castillo; Diana Peiteado; Alejandro Villalba; Emilio Martín-Mola
Journal:  Clin Exp Rheumatol       Date:  2012-05-10       Impact factor: 4.473

3.  Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study.

Authors:  Pierluigi Macchioni; Luigi Boiardi; Mariagrazia Catanoso; Giulia Pazzola; Carlo Salvarani
Journal:  Ann Rheum Dis       Date:  2013-12-02       Impact factor: 19.103

4.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Authors:  Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-01

5.  Management guidelines and outcome measures in polymyalgia rheumatica (PMR).

Authors:  B Dasgupta; E L Matteson; H Maradit-Kremers
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

6.  Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.

Authors:  Roberto Caporali; Marco A Cimmino; Gianfranco Ferraccioli; Roberto Gerli; Catherine Klersy; Carlo Salvarani; Carlomaurizio Montecucco
Journal:  Ann Intern Med       Date:  2004-10-05       Impact factor: 25.391

7.  Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica.

Authors:  Andrew Hutchings; Jane Hollywood; Donna L Lamping; Colin T Pease; Kuntal Chakravarty; Barbara Silverman; Ernest H S Choy; David G I Scott; Brian L Hazleman; Brian Bourke; Nagui Gendi; Bhaskar Dasgupta
Journal:  Arthritis Rheum       Date:  2007-06-15

8.  Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.

Authors:  Michele F Doran; Cynthia S Crowson; W Michael O'Fallon; Gene G Hunder; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

Review 9.  Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Authors:  Sarah L Mackie; Seher Arat; Jose da Silva; Catia Duarte; Sue Halliday; Rod Hughes; Marianne Morris; Colin T Pease; Jeffrey W Sherman; Lee S Simon; Maggie Walsh; René Westhovens; Samy Zakout; John R Kirwan
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

10.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103
View more
  2 in total

1.  [68/f-Muscle stiffness-like pain for 3 weeks : Preparation for the medical specialist examination: part 34].

Authors:  N Venhoff
Journal:  Internist (Berl)       Date:  2021-04-26       Impact factor: 0.743

2.  Opioid use in patients with polymyalgia rheumatica.

Authors:  Michael D Richter; Sara J Achenbach; Jorge A Zamora-Legoff; Cynthia S Crowson; Eric L Matteson
Journal:  Clin Exp Rheumatol       Date:  2017-06-29       Impact factor: 4.473
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.